Liminal BioSciences Inc. LMNL
Sep 25, 2023, 3:59 PM EDT
- Market cap
- 27.62M
- Revenue (ttm)
- 537.00K
- Profit margin
- 702.61%
- EPS (ttm)
- -6.83
- Shares out
- 3.10M
- P/E ratio
- -1.24
- Forward P/E
- -0.92
- Volume
- 5.05K
- Avg volume
- 23.73K
- Open
- 8.48
- Previous close
- 8.50
- Day's range
- 8.48 – 8.50
- 52-week range
- 3.10 – 8.50
- Beta
- 29.84
- Analysts
- Hold
- Price target
- 7.53 (-11.4%)
- Earnings date
- Nov 8, 2023
1Y +3.65 (+75.26%)
Key statistics
- Enterprise value
- 273.17K
- PEG ratio
- 0.00
- Price / sales
- 48.50
- Price / book
- 0.90
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -25.90M
- Total cash
- 26.94M
- Total debt
- 1.36M
- Return on equity
- -96.58%
- Short % of float
- 2.57%
- 50-day average
- 6.68
- 200-day average
- 5.28
Analyst view
Consensus: hold
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 8, 2023
Expected Nov 8, 2023. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 8, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 9, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| Mar 15, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 9, 2022 | Sep 1, 2022 | 0.00 | — | — | — |
| Aug 9, 2022 | Jun 1, 2022 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 24, 2021 | HC Wainwright & Co. | down | Buy | Neutral |
| Jun 2, 2021 | Piper Sandler | down | Overweight | Neutral |
| Feb 18, 2021 | HC Wainwright & Co. | init | — | Buy |
| Dec 21, 2020 | Piper Sandler | init | — | Overweight |
About Liminal BioSciences Inc.
Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- liminalbiosciences.com
News
Why SeaChange International Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket 
Why Kura Sushi Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session 
Markets Mixed; US Trade Deficit Widens In February 
Earnings Scheduled For March 15, 2023 - Stocks That Hit 52-Week Lows On Tuesday
Stocks That Hit 52-Week Lows On Friday - Stocks That Hit 52-Week Lows On Thursday
- Stocks That Hit 52-Week Lows On Wednesday
- Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday
Stocks That Hit 52-Week Lows On Friday
Your note
Sign in to keep a note on LMNL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Best (Simon Geoffrey) | Director of Issuer | Acquisition or disposition in the public market | Mar 23, 2022 | 0 |
| Iskra, Marie | Senior Officer of Issuer | Acquisition or disposition in the public market | Sep 11, 2022 | 0 |
| Wach (Timothy Steven) | Director of Issuer | Acquisition or disposition in the public market | Mar 21, 2022 | 200 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Susquehanna International Group, LLP | 0.46% | 14,133 | 118.58K | Mar 30, 2023 |
| National Bank of Canada/FI | 0.32% | 9,853 | 82.67K | Mar 30, 2023 |
| Estabrook Capital Management | 0.02% | 500 | 4.20K | Mar 30, 2023 |
| Royal Bank of Canada | 0.02% | 502 | 4.21K | Mar 30, 2023 |
| UBS Group AG | 0.00% | 48 | 402 | Mar 30, 2023 |
| Tanaka Capital Management Inc | 0.00% | 1 | 8 | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.07% | 2,273 | 19.07K | Feb 27, 2023 |